Abstract
Since the introduction of targeted biological therapies, the implications of a new diagnosis of rheumatoid arthritis have changed dramatically. There are now several therapeutic options available for these patients and the target of treatment - remission - is now a realistic goal.
MeSH terms
-
Abatacept
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Humans
-
Immunoconjugates / therapeutic use
-
Immunotherapy*
-
Methotrexate / therapeutic use
-
Molecular Targeted Therapy
-
Prognosis
-
Randomized Controlled Trials as Topic
-
Remission Induction
-
Rituximab
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Immunoconjugates
-
Tumor Necrosis Factor-alpha
-
Rituximab
-
Abatacept
-
tocilizumab
-
Methotrexate